Barclays analyst Luke Sergott raised the firm’s price target on Icon (ICLR) to $200 from $185 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- Jefferies says market thinking ‘backwards’ on FDA one trial proposal
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Icon’s Hold Rating: Navigating Leadership Transition and Customer Challenges Amid Market Recovery
- Icon initiated with a Market Perform at BMO Capital